Figure 3.
Figure 3. Effects of 1-MT on number of IFN-γ-secreting human CD8+ cells and HIV-1-specific CD8+ precursors. Number of IFN-γ-secreting cells in the peripheral blood one week after HIV-1 MDM injection (A,B). Representative histograms of human CD8/IFN-γ cells in control and 1-MT-treated groups are shown in panel A. Average percentage of IFN-γ-secreting cells (n = 7 and n = 8 for control and 1-MT mice, respectively) in peripheral blood (1-3 weeks) (B). Percentage of HIV-1gag (SL-9) tetramer-positive human CD8+ cells from spleen expanded by PHA/IL-2 stimulated in vitro 3 weeks after HIV-1 MDM injection (C). Two left panels are control animals, 2 right panels are 1-MT-treated mice. Error bars indicate SEM. *P < .05 (1-MT versus vehicle control).

Effects of 1-MT on number of IFN-γ-secreting human CD8+ cells and HIV-1-specific CD8+ precursors. Number of IFN-γ-secreting cells in the peripheral blood one week after HIV-1 MDM injection (A,B). Representative histograms of human CD8/IFN-γ cells in control and 1-MT-treated groups are shown in panel A. Average percentage of IFN-γ-secreting cells (n = 7 and n = 8 for control and 1-MT mice, respectively) in peripheral blood (1-3 weeks) (B). Percentage of HIV-1gag (SL-9) tetramer-positive human CD8+ cells from spleen expanded by PHA/IL-2 stimulated in vitro 3 weeks after HIV-1 MDM injection (C). Two left panels are control animals, 2 right panels are 1-MT-treated mice. Error bars indicate SEM. *P < .05 (1-MT versus vehicle control).

Close Modal

or Create an Account

Close Modal
Close Modal